ZIVO Bioscience, Inc. (ZIVO)
OTCMKTS
· Delayed Price · Currency is USD
8.50
-0.75 (-8.11%)
Mar 9, 2026, 2:36 PM EST
ZIVO Bioscience Employees
ZIVO Bioscience had 7 employees as of December 31, 2024. The number of employees decreased by 1 or -12.50% compared to the previous year.
Employees
7
Change (1Y)
-1
Growth (1Y)
-12.50%
Revenue / Employee
$29,861
Profits / Employee
-$1,212,266
Market Cap
37.49M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Apparatus Regenerative Technology | 8 |
| Cell Source | 1 |
| Vicapsys Life Sciences | 2 |
| NKGen Biotech | 26 |
| Nuo Therapeutics | 9 |
| Provectus Biopharmaceuticals | 6 |
| Finch Therapeutics Group | 1 |
| Oncotelic Therapeutics | 26 |
ZIVO Bioscience News
- 6 months ago - ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses - Business Wire
- 9 months ago - ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry - Business Wire
- 10 months ago - University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry - Business Wire
- 1 year ago - ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry - Business Wire
- 1 year ago - ZIVO Bioscience to Present at The Microcap Conference 2025 - Business Wire
- 1 year ago - ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities - Business Wire
- 1 year ago - ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza - Business Wire
- 1 year ago - ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens - Business Wire